Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus FOLFIRI as Second-line Therapy for HER2-negative Advanced Gastric Cancer
NCT06365008Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2036
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in gastric cancer (GC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Progression-Free Survival Rate at 5 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06365008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365008.